Patents Assigned to ACENDA PHARMA INC.
  • Patent number: 9850219
    Abstract: The present disclosure relates to phenothiazine derivatives such as conjugates of phenothiazine compounds, as well as pharmaceutical compositions thereof. The present disclosure also relates to a method of making and the use of such compounds for treating cancer, e.g., a lung cancer, a colon cancer, breast cancer or pancreatic cancer.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: December 26, 2017
    Assignee: Acenda Pharma, Inc.
    Inventors: Haiyung Cheng, Chi-Feng Lin, Jhen-Hua Shih, Alexander C. H. Wu
  • Patent number: 9695138
    Abstract: The present disclosure relates to phenothiazine derivatives such as conjugates of phenothiazine compounds, as well as pharmaceutical compositions thereof. The present disclosure also relates to a method of making and the use of such compounds for treating cancer, e.g., a lung cancer, a colon cancer, breast cancer or pancreatic cancer.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: July 4, 2017
    Assignee: Acenda Pharma, Inc.
    Inventors: Haiyung Cheng, Chi-Feng Lin, Jhen-Hua Shih, Alexander C. H. Wu
  • Publication number: 20140121178
    Abstract: The present invention relates to a method and an improved composition for improving the absorption of an ester prodrug in a subject. The method includes co-administering to the subject an effective amount of the ester prodrug or a pharmaceutical acceptable salt thereof, and a sufficient amount of adjuvant to impede a carboxylesterase-mediated hydrolysis of the ester prodrug in vivo, wherein the adjuvant is selected from the gnzup consisting of triacetin, triethyl citrate and a combination of both. The present invention also relates to a method for impeding carboxylesterase-mediated hydrolysis of esters, including ester prodrugs.
    Type: Application
    Filed: June 24, 2011
    Publication date: May 1, 2014
    Applicant: ACENDA PHARMA INC.
    Inventor: Haiyung Cheng